GLS and cancer: GLS1 is associated with different types of cancer, and the GLS1 inhibitor, BPTES, combined with the phosphodiesterase-5 inhibitor, zaprinast, increases the sensitivity of pancreatic CSCs to radiotherapy and promotes apoptosis by increasing the level of intracellular ROS431.